The BPDAI urticaria/erythema subscore serves as a reliable clinical surrogate for a Th2-driven molecular endotype in BP. The identification of a specific Th2-ligand/JAK-STAT-signaling circuit in the inflammatory phenotype supports a stratified treatment approach, suggesting that patients with a high inflammatory burden may benefit from targeted type 2 immunotherapies or JAK inhibitors, which warrants further prospective validation.
Cao et al. (Tue,) studied this question.